Meeting
2021 Gastrointestinal Cancers Symposium
Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).
Authors
Guillem Argiles
Vall d’Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, TTD Group, Barcelona, Spain
Guillem Argiles , Christiane Jungels , Rocio Garcia-Carbonero , Marc Diez Garcia , Johanna C. Bendell , Josep Tabernero , Mohamed Bekradda , Jeroen Lammerts van Bueren , Kees Bol , Viktoriya Stalbovskaya , Szabolcs Fatrai , Arjen Brinkman , Ernesto Wasserman , Antoine Hollebecque
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03526835
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 62)
DOI
10.1200/JCO.2021.39.3_suppl.62
Abstract #
62
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
First Author: Georg Martin Haag
Poster
2023 ASCO Annual Meeting
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
First Author: Jayesh Desai
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
First Author: Chao Yin